Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
Hankey
Graeme J
GJ
Stroke Unit, Royal Perth Hospital, 197 Wellington Street Perth, Australia 6001. gjhankey@cyllene.uwa.edu.au
Klijn
Catharina J M
CJ
Eikelboom
John W
JW
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D001596:Benzylamines; D002170:Canada; D004311:Double-Blind Method; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D012306:Risk; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013917:Thrombin / Q000037:antagonists & inhibitors; D016896:Treatment Outcome; D014481:United States; D014812:Vitamin K / Q000037:antagonists & inhibitors; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D014812:Vitamin K; C426686:ximelagatran; D014859:Warfarin; D013917:Thrombin